Diffusion Pharmaceuticals Inc.
DFFN
$0.41
Change (1 day)
$14.37
Year High
$4.14
Year Low
Categories
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Earnings for Diffusion Pharmaceuticals Inc. (DFFN)
Earnings in 2022 (TTM): $-15,591,428
According to Diffusion Pharmaceuticals Inc.'s latest financial reports the company's current earnings (TTM) are $-15,591,428. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Diffusion Pharmaceuticals Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-15,591,428 | $-15,210,676 |
| 2021 | $-24,539,620 | $-24,095,727 |
| 2020 | $-15,860,687 | $-14,185,306 |
| 2019 | $-11,466,494 | $-11,799,379 |
| 2018 | $-18,807,099 | $-18,369,810 |
| 2017 | $-2,420,203 | $-1,364,518 |
| 2016 | $-18,401,415 | $-18,036,619 |
| 2015 | $-23,820,675 | $-23,820,675 |
| 2014 | $-17,169,708 | $-14,352,824 |
| 2013 | $-2,457,949 | $-2,464,350 |
| 2012 | $-6,849,816 | $-6,849,815 |
| 2011 | $-15,837,168 | $-15,837,168 |
| 2010 | $-8,409,605 | $-8,409,605 |
| 2009 | $-3,918,986 | $-3,401,098 |
| 2008 | $-906,778 | $-1,093,267 |
| 2007 | $-60,762 | $-60,762 |
| 2006 | $-48,096 | $-48,096 |
| 2005 | $-94,863 | $-94,863 |
| 2004 | $-2,710,000 | $-2,850,000 |
| 1999 | $-6,449,984 | $-8,060,282 |
| 1998 | $ | $200 K |